Paul Fonteyne named president, CEO of Boehringer Ingelheim USA
Paul R. Fonteyne has been promoted to U.S. country managing director and president and CEO of Boehringer Ingelheim USA. Fonteyne assumes this role from J. Martin Carroll, who remains with the company in a corporate strategy and development role and a member of the board.
Fonteyne previously was corporate senior vice president for Boehringer Ingelheim USA, responsible for leading the global marketing strategy supporting the company’s prescription medicines business. In this role, he helped drive growth in the company's core areas of respiratory and cardiovascular disease, as well as positioned it to enter new areas of diabetes and oncology.
"I have worked with Paul for more than 15 years, and am confident that his depth and breadth of experience, combined with his passion for finding new ways to bring medicines to patients makes him well suited to take on this role and help lead the company to even greater success,” said Carroll.